The most read stories from across Cardiovascular News in April 2022 include highlights and late-breaking data from the American College of Cardiology’s annual scientific sessions (ACC 2022, 2–4 April, Washington DC, USA), as well as evidence-based recommendations for percutaneous transaxillary arterial access and training for clinicians.
- Analysis finds lower rate of structural valve deterioration with TAVI than SAVR at five years
Patients who received a transcatheter supra-annular self-expanding heart valve had less structural deterioration in the valve after five years compared with similar patients who received a biologic valve surgically.
- FFR-guided PCI non-inferior to IVUS for intermediate coronary stenosis
A head-to-head comparison of fractional flow reserve (FFR) and intravascular ultrasound (IVUS) guided percutaneous coronary intervention (PCI) in patients with intermediate coronary artery stenosis found that FFR was non-inferior to IVUS for adverse clinical outcomes at a two-year follow-up.
- Corvia announces publication of REDUCE LAP-HF II data
Corvia Medical announced publication of analyses from its global, phase III REDUCE LAP-HF II randomised trial of heart failure (HF) patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction.
- “Promising” one-year results for Pascal device in CLASP-TR trial
Patients with tricuspid regurgitation (TR) who received a Pascal transcatheter valve (Edwards Lifesciences) experienced significant improvements in blood flow through the heart and in quality of life at one year.
- Three-year data show “durable blood pressure reductions” through renal denervation
Long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial have been presented during a featured clinical research session at the American College of Cardiology’s annual scientific sessions (ACC 2022, 2–4 April, Washington DC, USA).
- FAME 3 shows FFR-guided PCI leads to a faster recovery versus surgery
Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) leads to a faster improvement in quality of life, with similar outcomes at 12-month follow-up compared with coronary artery bypass graft (CABG) surgery.
- NACMI registry finds reducing rates of death among STEMI patients with COVID-19
Latest results from the North American COVID-19 STEMI (NACMI) registry reported a 25% reduction in early mortality in 2021 compared to 2020 among patients with ST-segment elevation myocardial infarction (STEMI) and COVID-19 infection and zero deaths for patients vaccinated against SARS-CoV-2.
- TAVI patients treated with edoxaban see fewer incidences of leaflet thrombosis compared to DAPT
Patients treated with edoxaban for six months after a transcatheter aortic valve implantation (TAVI) procedure experienced fewer incidences of leaflet thrombosis compared to patients receiving dual antiplatelet therapy (DAPT).
- First patient enrolled in BIOMICS study for CTO-PCI
Biosensors International has announced the enrolment of the first patient in the BIOMICS study, a prospective, multicentre evaluation of the safety and effectiveness of the Biosensors Microcatheter in patients undergoing percutaneous coronary intervention (PCI) for the treatment of chronic total occlusions (CTO).
- SCAI issues position paper on transaxillary arterial access
The Society for Cardiovascular Angiography & Interventions (SCAI) has released an official position statement providing evidence-based recommendations for percutaneous transaxillary arterial access and training for clinicians.